Daily Respiratory Research Analysis
Three impactful respiratory studies emerged today: a multicenter randomized trial showed that extending caffeine therapy to 42–43 weeks PMA significantly reduces intermittent hypoxia in preterm infants; a first head-to-head RCT found a 40% FiO2 threshold for surfactant administration non-inferior to 30%, reducing surfactant exposure; and a national modeling analysis estimated substantial RSV burden among Indian children under five in 2020, supporting immunization strategies.
Summary
Three impactful respiratory studies emerged today: a multicenter randomized trial showed that extending caffeine therapy to 42–43 weeks PMA significantly reduces intermittent hypoxia in preterm infants; a first head-to-head RCT found a 40% FiO2 threshold for surfactant administration non-inferior to 30%, reducing surfactant exposure; and a national modeling analysis estimated substantial RSV burden among Indian children under five in 2020, supporting immunization strategies.
Research Themes
- Neonatal respiratory care optimization
- Evidence-based thresholds for surfactant therapy
- RSV disease burden informing immunization policy
Selected Articles
1. Intermittent hypoxia and caffeine in infants born preterm: the ICAF Randomized Clinical Trial.
In a multicenter, masked randomized trial of 160 very preterm infants, extending caffeine through 42–43 weeks PMA significantly reduced time with SpO2 <90% at every PMA timepoint (e.g., ~173 vs 85 s/h at 34 weeks; ~73 vs 27 s/h at 41 weeks) and lowered TNF-α by 23%. No significant differences were observed on brain MRI or other inflammatory biomarkers.
Impact: This is high-quality randomized evidence demonstrating a simple, scalable intervention that reduces intermittent hypoxia—an exposure linked to adverse neurodevelopmental outcomes—in preterm infants.
Clinical Implications: Consider extending caffeine therapy beyond traditional discontinuation at ~36–37 weeks PMA to 42–43 weeks in stable preterm infants to reduce intermittent hypoxia exposure, with monitoring for safety and individualized weaning.
Key Findings
- Extended caffeine (to 42–43 weeks PMA) reduced seconds/hour with SpO2 <90% at every PMA assessed (e.g., ~173 vs 85 s/h at 34 weeks; ~73 vs 27 s/h at 41 weeks).
- TNF-α decreased by 23% in the caffeine group versus placebo at follow-up.
- No significant differences were detected on brain MRI or across most inflammatory biomarkers.
Methodological Strengths
- Multicenter, masked randomized controlled design
- Continuous pulse oximetry and predefined biomarker assessments
Limitations
- Sample size modest for rare safety outcomes and long-term neurodevelopment
- Generalizability limited to room-air, convalescing preterm infants
Future Directions: Assess long-term neurodevelopmental outcomes and refine criteria for individualized caffeine weaning beyond 42 weeks PMA.
OBJECTIVE: To determine whether extending caffeine therapy through 43 weeks' postmenstrual age (PMA) decreases intermittent hypoxia (IH) in convalescing preterm infants. Secondary objectives were to assess caffeine effects on changes in inflammation-related plasma biomarkers and brain MRI. DESIGN: Multicentre masked randomised trial. SETTING: 16 US hospitals. PATIENTS: Infants at <30 weeks + 6 days gestational age on caffeine between 32 weeks and 36+5 days PMA in room air with routine caffeine discontinuation prior to 36 weeks +6 days. INTERVENTION: Randomisation to caffeine or placebo and treated through 42 completed weeks. Pulse oximetry was recorded from enrolment through 1 week after stopping study drug. Blood for 12 inflammation-related biomarkers obtained at enrolment and 38 weeks' PMA and brain imag
2. Higher (40%) versus lower (30%) FiO2 threshold for surfactant administration in preterm neonates with RDS: a non-inferiority randomized controlled trial.
In 205 preterm neonates with RDS stabilized on CPAP, initiating surfactant at an FiO2 threshold of 40% was non-inferior to 30% for total respiratory support duration and did not increase adverse outcomes (BPD ≥2, air leaks, hsPDA, mortality, length of stay). The 40% threshold reduced surfactant exposure and may decrease NICU workload, especially in resource-limited settings.
Impact: This is the first RCT directly comparing FiO2 thresholds for surfactant administration, challenging prevailing practice and offering a safe, cost-efficient threshold that reduces interventions.
Clinical Implications: Clinicians can consider a 40% FiO2 threshold for surfactant in CPAP-stabilized preterm infants with RDS to reduce surfactant use without compromising outcomes, with local protocols updated accordingly.
Key Findings
- A 40% FiO2 threshold was non-inferior to 30% for total duration of respiratory support.
- No increase in key adverse outcomes (BPD ≥2, air leaks, hsPDA requiring treatment, mortality, hospital stay).
- Reduced surfactant exposure with a 40% threshold, suggesting potential cost and workload benefits.
Methodological Strengths
- Randomized, non-inferiority design focused on a pragmatic clinical threshold
- Comprehensive secondary outcomes including major prematurity morbidities
Limitations
- Single-trial, modest sample size; precision for rare adverse events is limited
- Blinding and multicenter generalizability not fully detailed in the abstract
Future Directions: Multicenter trials to validate the 40% threshold across diverse settings and to assess long-term respiratory and neurodevelopmental outcomes.
UNLABELLED: The optimal FiO₂ threshold for surfactant administration in preterm neonates with respiratory distress syndrome (RDS) remains uncertain, with limited evidence supporting current guideline recommendations. The objective was to compare the total duration of respiratory support between two FiO₂ thresholds for surfactant administration in preterm neonates stabilized on CPAP. In this non-inferiority randomized control trial (RCT), preterm neonates (26-32 weeks' gestation) with RDS were randomized at 1 h of life to receive surfactant at FiO₂ thresholds of either 40% or 30%. The primary outcome was total duration of respiratory support. The secondary outcomes were requirement of surfactant within 6 h after birth, requirement of repeat dose of surfactant, common morbidities of prematurity bronchopulmonary dysplasia (BPD) stage ≥ 2, air leaks, hemodynamically significant patent ductus arteriosus (hsPDA) (requiring treatment), all-cause mortality, and total duration of hospital stay. Subgroup analysis for gestation between 26 and 29 weeks was done. A total of 205 neonates with a mean birth weight of 1237.92 ± 328.89 g and a mean gestation age of 30.06 ± 1.85 weeks were enrolled. The mean duration of respiratory support was 140.8 h in 40% FiO
3. Disease burden due to respiratory syncytial virus infection among under-5 children of India for 2020: a multiplicative model using meta-estimates.
Using 36 studies and a multiplicative modeling approach, India’s 2020 under-5 RSV burden was estimated at ~12.6 million ALRI cases, ~8.5 million outpatient visits, ~1 million hospitalizations, and ~36,700 deaths; 87% of deaths occurred in infants <1 year. Findings support prioritizing RSV prevention (maternal vaccination, nirsevimab) and establishing surveillance to close data gaps.
Impact: Robust national burden estimates inform cost-effectiveness and rollout strategies for RSV prevention in a high-burden setting, directly supporting policy decisions.
Clinical Implications: Health systems should prioritize RSV immunization strategies (maternal RSVpreF, infant nirsevimab), and build surveillance platforms to target infants <1 year and high-risk groups (e.g., preterm).
Key Findings
- Estimated ~12.6M RSV-ALRI cases, ~8.5M outpatient visits, ~1.0M hospitalizations in under-5s in India (2020).
- Estimated ~36,700 RSV-ALRI deaths; 87% occurred in infants under 1 year.
- Identified data gaps: early infancy, preterm/high-risk populations, and geographic representativeness.
Methodological Strengths
- Systematic meta-analysis with national modeling and Monte Carlo uncertainty
- Inclusion of unpublished data and multiple data sources
Limitations
- Reliance on modeling assumptions and heterogeneous source studies
- Limited primary data for early infancy, preterm infants, and some regions
Future Directions: Establish RSV surveillance and prospective cohort platforms capturing early infancy and high-risk groups to refine burden and evaluate immunization impact.
BACKGROUND: Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infections (ALRI) among under-5 (U5) children. Generating evidence on disease burden is important to inform decisions regarding RSV preventive strategies. This systematic analysis estimated RSV-associated burden in U5 children for 2020 in India and identified data needs for decision-making regarding preventive strategies. METHODS: We conducted meta-analyses of published studies from India between January 2000 and July 2021 and used multiplicative models by applying ALRI and RSV meta-estimates to population estimates for 2020 and national pneumonia deaths. Uncertainty ranges (UR) were calculated using Monte Carlo simulations. RESULTS: Using 36 eligible studies including unpublished data from three studies, we estimated 12.6 (UR: 9.9-15.2) million RSV-ALRI cases; 8.5 (UR: 6.7-10.3) million RSV-ALRI outpatient visits and 1 (UR: 0.9-1.2) million RSV-ALRI hospitalisations among U5 children in India in 2020. We estimated 36 700 RSV-ALRI overall deaths (UR: 31 200-42600) of which 27 400 (UR: 20 100-34200) were in-hospital deaths in children aged <5 years. One in four RSV-ALRI cases and 87% of all deaths occurred in children aged <1 year. Key data gaps identified were limited data availability for early infancy, high-risk groups like preterm infants and poor geographical representativeness. CONCLUSIONS: RSV burden contributed to 4.4% of U5 deaths in India for 2020. Public health interventions against RSV, including establishment of surveillance/research platforms to address data gaps and enable impact assessment, are required. PROSPERO REGISTRATION NUMBER: CRD42020213433.